ArticleFrontiers in oncology2022
Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Ovarian squamous cell carcinoma: clinicopathological features, prognosis and immunotherapy outcomes.Journal of gynecologic oncology · 2025Article
- Immunotherapy in young adults with mature cystic ovarian Teratoma-Derived squamous cell carcinoma: a case series.Journal of ovarian research · 2025Article
- Malignant transformation of an ovarian mature teratoma diagnosed 17 years ago: a case report and literature review of treatment with immune checkpoint inhibitors.International cancer conference journal · 2025Article
- Stage IV malignant transformation of mature cystic teratoma palliatively treated with concurrent chemoradiotherapy: A case report.World journal of clinical cases · 2025Article
- Squamous cell carcinoma malignant transformation in mature cystic teratoma of the ovary: a case report and review of the literature.Journal of medical case reports · 2024Review
- Ruptured Ovarian Mature Cystic Teratoma with Adenocarcinoma Transformation: A Case Report.International journal of women's health · 2024Article
- Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma.Cancer science · 2023Article
- Nivolumab for malignant transformation of ovarian mature cystic teratoma.Gynecologic oncology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant transformations, such as ovarian squamous cell carcinoma (SCC) in ovarian mature cystic teratoma (OMCT), are rare tumors. The management of recurrent disease is still a challenge, and the gene mutations involved remain unclear. We herein report a recurrent case of ovarian SCC with a PIK3CA gene variation and immunohistochemical staining of programmed death-ligand 1 (PD-L1) >10%. This patient achieved clinical remission after platinum-based effective chemotherapy and programmed death 1 (PD-1) immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.